Form 4: BridgeBio Officer Sells Shares for Tax Obligations

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, disposed of 4,781 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc. (BBIO), reported a transaction on November 16, 2025.
• The transaction involved the disposition of 4,781 shares of Common Stock.
• These shares were withheld to satisfy tax obligations incurred from the vesting of 9,410 Restricted Stock Units (RSUs).
• The shares were disposed of at a price of $66.39 per share.
• Following this transaction, Maricel Apuli beneficially owns 132,297 shares of BridgeBio Pharma Common Stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction (tax withholding) related to RSU vesting, which is neutral in terms of company performance or outlook.

Industry Context

This is a routine insider transaction related to equity compensation and tax obligations, which is common across all industries for executives receiving Restricted Stock Units.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction by an insider for tax purposes, not indicative of a change in sentiment or company fundamentals.
• Employees: The vesting of RSUs is a positive event for the employee, representing earned compensation.

Key Dates

Recommendation

This Form 4 filing details a routine tax-related disposition of shares by a Chief Accounting Officer following RSU vesting. Such transactions are common and typically not indicative of any change in the company's fundamental performance or future prospects. Therefore, it does not provide new information that would warrant a change in investment recommendation.

Keywords

BridgeBio Pharma, BBIO, Form 4, Insider Transaction, Stock Sale, Tax Withholding, RSU Vesting, Maricel Apuli